Author/Editor		Bren, Andrej
Title		Mycophenolate mofetil in renal transplantation
Type		članek
Source		In: Mešić E, editor. Finalni program, pozvana predavanja i knjiga sažetaka 2. nefrološki kongres Bosne i Hercegovine; 2005 apr 6-9; Tuzla. Tuzla: PrintCom,
Publication year		2005
Volume		str. 69-74
Language		eng
Abstract		Mycophenolate mofetil (MMF), an immunosuppressive drug, inhibits inosine monophospate dehydrogenase (IMPHD), a key enzyme in de novo purine synthesis of lymphocytes, leading to selective lymphocyte suppression. MMF is rapidly and completely absorbed following oral administration. Studies of administration with cyclosporine and corticosteroides suggested a significant reduction in the incidence of organ rejection at dosage of 1 to 3 g/day. The adverse effects are similar to that of azathioprine, including mostly gastrointestinal tract, hematologic system and increased frequency of opportunistic infections. MMF offers improved immunossupressive therapy following renal transplantation. MMF has been introduced for prevention of acute renal allograft rejection in most countries since 1995, in Slovenia since 1997. It has been used in different combinations of immunosuppressive drugs and in various dosage regimens.
Descriptors		KIDNEY TRANSPLANTATION IMMUNOSUPPRESSIVE AGENTS MYCOPHENOLIC ACID TREATMENT OUTCOME